# US 2018/0022810 A1 · Use of cxcr3 inhibitors for protecting against fetal wastage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022810 A1
- Document ID: US20180022810A1
- Status: Published application
- Kind: A1
- Application number: 15/548,814
- Filed: 2016-02-04
- Published: 2018-01-25
- Earliest claimed: 2015-02-05
- Assignees: Children's Hospital Medical Center
- Applicants: Children's Hospital Medical Center
- Inventors: Sing Sing Way
- Web page: https://patentgrep.com/patent/US20180022810A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/249: {Interferons}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2812: {against CD4}
- C07K 16/2815: {against CD8}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are compositions and methods related to reducing the risk of or preventing fetal wastage in a subject using a CXCR3 inhibitor.

## Claims

### Claim 1

A method of reducing the risk of or preventing fetal wastage, the method comprising:
administering to a pregnant subject a CXCR3 inhibitor in an amount effective to reduce the risk of or prevent fetal wastage.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has or is at risk of having an infection, a stillbirth, preeclampsia or a premature infant.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject has or is at risk of having an infection.

### Claim 4 (depends on 3)

The method of claim 3, wherein the infection is caused by a pathogen selected from the group consisting of Listeria monocytogenes, Influenza A, herpes simplex virus, Lymphocytic Choriomeningitis Virus (LCMV), Salmonella, Plasmodium, Toxoplasma, Escherichia coli, CMV (cytomegalovirus), parvovirus, or Leishmania spp.

### Claim 5 (depends on 4)

The method of claim 4, wherein the infection is caused by Listeria monocytogenes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pregnant subject is a human female subject.

### Claim 7 (depends on 3)

The method of claim 3, wherein the CXCR3 inhibitor is administered prior to the infection or prior to manifestation of a symptom of the infection.

### Claim 8 (depends on 3)

The method of claim 3, wherein the CXCR3 inhibitor is administered to the subject within 7 days after the subject is infected with a pathogen or manifests a symptom of the infection.

### Claim 9 (depends on 1)

The method of claim 1, wherein the CXCR3 inhibitor is selected from the group consisting of an interfering RNA, an antisense oligonucleotide, a small molecule, and an antibody.

### Claim 10 (depends on 9)

The method of claim 9, wherein the CXCR3 inhibitor is an antibody that specifically binds to CXCR3.

### Claim 11 (depends on 10)

The method of claim 10, wherein the CXCR3 is human CXCR3.

### Claim 12 (depends on 10)

The method of claim 10, wherein the antibody is a human antibody or a humanized antibody.

### Claim 13 (depends on 1)

The method of claim 1, wherein the amount of the CXCR3 inhibitor is effective to inhibit fetal-specific CD8+ T cells in the subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein the CXCR3 inhibitor is administered orally.

### Claim at position 15

-29. (canceled)
